Shares of Medtronic PLC MDT rallied 2.27% to $89.94 Friday, on what proved to be an all-around poor trading session for the ...
Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...
Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
Shares of Medtronic PLC MDT advanced 1.08% to $87.94 Thursday, on what proved to be an all-around rough trading session for ...
Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat.
CEO Geoff Martha said Medtronic would submit its application for urological procedures to the Food and Drug Administration by ...
In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.
Truist Financial analyst Richard Newitter maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of $93.00.
Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback